JP2012501313A5 - - Google Patents

Download PDF

Info

Publication number
JP2012501313A5
JP2012501313A5 JP2011524404A JP2011524404A JP2012501313A5 JP 2012501313 A5 JP2012501313 A5 JP 2012501313A5 JP 2011524404 A JP2011524404 A JP 2011524404A JP 2011524404 A JP2011524404 A JP 2011524404A JP 2012501313 A5 JP2012501313 A5 JP 2012501313A5
Authority
JP
Japan
Prior art keywords
amino
pyridin
cycloalkyl
quinazolin
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011524404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501313A (ja
JP5584215B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/061188 external-priority patent/WO2010026122A1/en
Publication of JP2012501313A publication Critical patent/JP2012501313A/ja
Publication of JP2012501313A5 publication Critical patent/JP2012501313A5/ja
Application granted granted Critical
Publication of JP5584215B2 publication Critical patent/JP5584215B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011524404A 2008-09-02 2009-08-31 ヘテロ環pimキナーゼ阻害剤 Expired - Fee Related JP5584215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9366408P 2008-09-02 2008-09-02
US61/093,664 2008-09-02
PCT/EP2009/061188 WO2010026122A1 (en) 2008-09-02 2009-08-31 Heterocyclic pim-kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012501313A JP2012501313A (ja) 2012-01-19
JP2012501313A5 true JP2012501313A5 (enExample) 2012-10-11
JP5584215B2 JP5584215B2 (ja) 2014-09-03

Family

ID=41170173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011524404A Expired - Fee Related JP5584215B2 (ja) 2008-09-02 2009-08-31 ヘテロ環pimキナーゼ阻害剤

Country Status (11)

Country Link
US (1) US8759338B2 (enExample)
EP (1) EP2344473B1 (enExample)
JP (1) JP5584215B2 (enExample)
KR (1) KR20110056399A (enExample)
CN (1) CN102197032B (enExample)
AU (1) AU2009289317A1 (enExample)
BR (1) BRPI0918846A2 (enExample)
CA (1) CA2735782A1 (enExample)
EA (1) EA201100427A1 (enExample)
MX (1) MX2011002362A (enExample)
WO (1) WO2010026122A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55634B1 (sr) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
HUE043732T2 (hu) 2007-06-13 2019-09-30 Incyte Holdings Corp Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Jak 저해물질로서 3-[4-(7h-피롤로[2,3-d]피리미딘-4-일)-1h-피라졸-1-일]옥탄- 또는 헵탄-니트릴
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI531572B (zh) 2010-03-10 2016-05-01 英塞特公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CR20190073A (es) 2012-11-15 2019-04-25 Incyte Holdings Corp FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
US9200004B2 (en) 2013-01-15 2015-12-01 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
SMT202100694T1 (it) 2013-03-06 2022-03-21 Incyte Holdings Corp Procedimenti e intermedi per produrre un inibitore di jak
CA2920108C (en) 2013-08-07 2022-07-05 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108373476B (zh) * 2017-01-13 2021-06-01 成都地奥制药集团有限公司 一种激酶抑制剂及其制备和应用
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
AU2019252793A1 (en) 2018-04-13 2020-10-15 Sumitomo Pharma America, Inc. PIM kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
CN111362922A (zh) * 2018-12-26 2020-07-03 上海喆邺生物科技有限公司 2,4-二氨基嘧啶衍生物及其用途
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk﹘5抑制劑和彼之用途
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312891D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
WO2004081000A1 (en) * 2003-03-10 2004-09-23 Astrazeneca Ab Quinazoline derivatives
WO2004108707A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
MXPA06003615A (es) * 2003-09-30 2006-06-05 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos.
US7781591B2 (en) * 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
JP2008501696A (ja) * 2004-06-04 2008-01-24 アンフォラ ディスカバリー コーポレーション Atp利用酵素阻害活性を示すキノリンおよびイソキノリン系化合物、ならびにその組成物および使用
ATE528302T1 (de) * 2005-08-29 2011-10-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
CL2007001737A1 (es) * 2006-06-13 2008-01-25 Wyeth Corp Compuestos derivados de cianopiridinas; inhibidores de proteina quinasa;composicion farmaceutica;y uso para el tratamiento o inhibicion de un trastorno mediado por una proteina quinasa,tal como enfermedad autoinmune e inflamatoria.
ES2528316T3 (es) * 2006-09-01 2015-02-06 Senhwa Biosciences, Inc. Moduladores de la serina-treonina proteína quinasa y de PARP
CA2689092C (en) * 2007-06-07 2013-01-15 Amgen Inc. Raf kinase modulators and methods of use

Similar Documents

Publication Publication Date Title
JP2012501313A5 (enExample)
JP2012501312A5 (enExample)
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
RU2498983C2 (ru) Соединения фениламинопиримидина и их применения
JP2017525757A5 (enExample)
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
RU2500673C2 (ru) Гетероциклические ингибиторы мек и способы их применения
EP1396487B1 (en) Phenylpyridine carbonyl piperazine derivative
JP2007519754A5 (enExample)
JP2017511794A5 (enExample)
JP2016528201A5 (enExample)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
JP2005529092A5 (enExample)
JP2014506599A5 (enExample)
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2014511869A5 (enExample)
RU2007132262A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2010526129A5 (enExample)
JP2013510876A5 (enExample)
JP2010534654A5 (enExample)
SI3106463T1 (en) Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase
JP2009506039A5 (enExample)
JP2003528859A5 (enExample)
NZ609955A (en) Sgc stimulators
JP2012503018A5 (enExample)